Powder: -20°C for 3 years | In solvent: -80°C for 1 year
IRAK4-IN-28 (compound 42), an orally-active IRAK4 inhibitor (IC50=8.9 nM), exhibits strong binding affinity with a Kd of 0.58 nM for the target enzyme. It is utilized for research purposes in the study of inflammation and autoimmune diseases [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,970.00 | |
50 mg | 8-10 weeks | $ 2,580.00 | |
100 mg | 8-10 weeks | $ 3,400.00 |
Description | IRAK4-IN-28 (compound 42), an orally-active IRAK4 inhibitor (IC50=8.9 nM), exhibits strong binding affinity with a Kd of 0.58 nM for the target enzyme. It is utilized for research purposes in the study of inflammation and autoimmune diseases [1]. |
In vitro | IRAK4-IN-28 does not inhibit cytochrome P450 enzymes CYP1A2, CYP2D6, CYP3A4, and hERG, indicating favorable safety and 'drug-like' properties [1]. However, it inhibits CYP2C9 and CYP2C19 with IC50 values of 12 μM and 2.7 μM, respectively [1]. It also exhibits high plasma protein binding in humans and rats (99.8% and 97.2%, respectively) [1]. Furthermore, IRAK4-IN-28 (1 h) dose-dependently suppresses LPS-induced TNF-α and IL-6 expression at mRNA and protein levels [1]. |
In vivo | IRAK4-IN-28 (compound 42) exhibits favorable pharmacokinetic data in a rat model [1]. It possesses oral bioavailability with a utilization rate of 68% [1]. At concentrations of 50 or 100 mg/ml, a single oral dose of IRAK4-IN-28 significantly reduces the release of the cytokines TNF-α and IL-6 induced by LPS in a mouse model [1]. |
Molecular Weight | 529.59 |
Formula | C27H31N9O3 |
CAS No. | 2952532-92-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
IRAK4-IN-28 2952532-92-0 Immunology/Inflammation NF-Κb IRAK inhibitor inhibit